Skip to content
value.today
Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc.

🇺🇸 Radnor, Pennsylvania, USABiotechnologyFounded 2017
Total raised
$88 M
2 rounds on record
Latest round
$50 M
Jan 2019
First round on record
Oct 2018
Today
Went public
See the company page

Cabaletta Bio, Inc. is listed today as Cabaletta Bio, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cabaletta Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2019$50 MNo. 2$50 to $250 million

Cabaletta Bio, Inc.: Raise no. 2, Jan 2019

Investors in this round

16 investors had bought by the notice of Jan 14, 2019: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Cabaletta Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,075,944
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan Geffken · Executive Officer
  • Steven Nichtberger · Executive Officer, Director
  • Brian Daniels · Director
  • Mark Simon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in all US states

Signed by Steven Nichtberger, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 14, 2019. Read the notice at the SEC.

equitySEC
Oct 2018$38 MNo. 1$10 to $50 million

Cabaletta Bio, Inc.: Raise no. 1, Oct 2018

Investors in this round

11 investors had bought by the notice of Dec 10, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Cabaletta Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dan Geffken · Executive Officer
  • Steven Nichtberger · Executive Officer, Director
  • Brian Daniels · Director
  • Mark Simon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Nichtberger, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 10, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cabaletta Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2019).

    SEC Form D · Jan 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2019

That is all the official record says: Cabaletta Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Cabaletta Bio, Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Cabaletta Bio, Inc.
InvestorKindAmountRoundRoleSource
5AM Partners V, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
5AM Ventures V, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Mgmt IV, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Private Design Fund IV, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Mark SimonPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2019)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Steven NichtbergerPersonnot statednot statedHeld Series A-1 preferred stock, director (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 16 investors.

Largest shareholders today

Institutions holding Cabaletta Bio, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cabaletta Bio, Inc.
NameRoleNamed in
Dan GeffkenExecutive officerJan 2019
Steven NichtbergerExecutive officerJan 2019
Brian DanielsDirectorJan 2019
Mark SimonDirectorJan 2019
Steven NichtbergerDirectorJan 2019

Went public since 2019. Its SEC number is that of a company listed on a stock exchange.